세계의 자가면역질환 진단 시장(-2031년) : 제품별, 검사 유형별, 질환 유형별, 최종 사용자별, 지역별 예측

The autoimmune disease diagnosis market is projected to reach USD 8.98 billion by 2031 from USD 5.57 billion in 2025, at a CAGR of 8.3% during the forecast period.

This growth is driven by the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and technological advancements such as multiplex immunoassays and biomarker-based tests. Additionally, the growing adoption of automated platforms and supportive government initiatives contribute to increased testing volumes and improved diagnostic accuracy.

By disease type, the systemic autoimmune diseases segment accounted for the largest market share in 2024.

Based on disease type, the global autoimmune disease diagnosis market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. The systemic autoimmune diseases segment accounted for the largest market share in 2024. The large share of this region is attributed to the widespread prevalence of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. These diseases typically affect multiple organs and systems, necessitating frequent and comprehensive diagnostic evaluations. The complexity of diagnosis, reliance on advanced immunological tests, and the need for continuous disease monitoring drive higher demand for diagnostic solutions in this segment.

By end user, the clinical laboratories segment accounted for the largest market share during the forecast period.

Based on end users, the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals & clinics, and other end users. Among these, the clinical laboratories segment accounted for the largest market share owing to specialized expertise, advanced diagnostic technologies, and high-throughput capabilities. Equipped with automated platforms such as ELISA, chemiluminescence, and immunofluorescence, these laboratories can perform complex tests with high accuracy and efficiency. Their role as centralized testing hubs allows them to process large sample volumes at reduced per-test costs.

Asia Pacific: The fastest-growing region in the autoimmune disease diagnosis market during the forecast period.

The autoimmune disease diagnosis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the region is primarily driven by the rising prevalence of autoimmune diseases, increasing healthcare expenditure, the growing adoption of advanced diagnostic technologies, and heightened awareness about early disease detection across emerging economies. Additionally, improvements in healthcare infrastructure and supportive government initiatives further contribute to market expansion in the Asia Pacific region.

The break-up of the profile of primary participants in the autoimmune disease diagnosis market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in the market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Grifols S.A. (Spain), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Exagen Inc. (US), Trinity Biotech plc (Ireland), Tecan Group Ltd. (Switzerland), Danaher Corporation (US), BIOSYNEX SA (France), QuidelOrtho Corporation (US), Revvity, Inc. (US), bioMerieux SA (France), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), SD Biosensor, INC. (Korea), Cambridge Life Sciences Ltd (UK), A. Menarini Diagnostics s.r.l (Italy), Sebia (France), KRONUS (US), Erba Group (Czech Republic), AESKU.GROUP GmbH (Germany), Medsource Ozone Biomedicals Pvt. Ltd. (India), and Epitope Diagnostics Inc. (US).

Research Coverage:

This research report categorizes the autoimmune disease diagnosis market by product (consumables and instruments), by test type (routine laboratory tests, inflammatory tests, autoantibodies and immunologic tests, urinalysis tests, and other tests), by disease type (systemic autoimmune diseases and organ-specific autoimmune diseases), by end user (clinical laboratories, hospitals & clinics, and other end users), and by region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the autoimmune disease diagnosis market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the autoimmune disease diagnosis market. This report covers the competitive analysis of upcoming startups in the autoimmune disease diagnosis market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall autoimmune disease diagnosis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (High incidence of autoimmune diseases, rising awareness related to early disease diagnosis, growing number of r&d activities for innovative diagnostic solutions, advancements in diagnostic technologies), restraints (high capital requirements), opportunities (utilization of biosensors for autoimmune disease diagnosis, growth potential of emerging economies, growing number of reagent rental agreements), and challenges (complexities associated with diagnosis of autoimmune diseases, shortage of skilled professionals) influencing the growth of the autoimmune disease diagnosis market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the autoimmune disease diagnosis market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the autoimmune disease diagnosis market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoimmune disease diagnosis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Revvity, Inc. (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 PARAMETRIC ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AUTOIMMUNITY DIAGNOSTICS MARKET OVERVIEW
• 4.2 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031
• 4.3 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031
• 4.4 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031
• 4.5 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031
• 4.6 AUTOIMMUNITY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 High incidence of autoimmune diseases
    • 5.2.1.2 Rising awareness related to early disease diagnosis
    • 5.2.1.3 Increasing number of R&D activities for innovative diagnostic solutions
    • 5.2.1.4 Advancements in diagnostic technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital requirements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Utilization of biosensors for autoimmune disease diagnosis
    • 5.2.3.2 Growth potential of emerging economies
    • 5.2.3.3 Growing number of reagent rental agreements
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complexities associated with diagnosis of autoimmune diseases
    • 5.2.4.2 Shortage of skilled professionals
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT, 2023-2025
  • 5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023-2025
  • 5.3.3 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA (HS CODE 3822)
  • 5.7.2 EXPORT DATA (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 BUYING CRITERIA
  • 5.10.3 REGULATORY LANDSCAPE
    • 5.10.3.1 North America
      • 5.10.3.1.1 US
      • 5.10.3.1.2 Canada
    • 5.10.3.2 Europe
      • 5.10.3.2.1 Germany
      • 5.10.3.2.2 UK
      • 5.10.3.2.3 France
      • 5.10.3.2.4 Italy
    • 5.10.3.3 Asia Pacific
      • 5.10.3.3.1 China
      • 5.10.3.3.2 Japan
      • 5.10.3.3.3 India
      • 5.10.3.3.4 Australia
    • 5.10.3.4 Latin America
    • 5.10.3.5 Middle East
      • 5.10.3.5.1 Africa
  • 5.10.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Immunoassays
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Flow cytometry
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 INVESTMENT & FUNDING SCENARIO
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: LABORATORY-BASED DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
  • 5.15.2 CASE STUDY 2: DIAGNOSTIC IMPORTANCE OF AUTOANTIBODY TESTING IN IDENTIFICATION OF LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA)
• 5.16 IMPACT OF AI/GENERATIVE AI ON AUTOIMMUNITY DIAGNOSTICS MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF AI
  • 5.16.3 AI USE CASES
  • 5.16.4 IMPLEMENTATION OF AI, BY KEY COMPANY AND CASE
  • 5.16.5 FUTURE OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET
• 5.17 TRUMP TARIFF IMPACT ON AUTOIMMUNITY DIAGNOSTICS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 KEY IMPACT ON COUNTRY/REGION
    • 5.17.4.1 North America
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
  • 5.17.5 IMPACT ON END-USE INDUSTRIES
    • 5.17.5.1 Clinical laboratories
    • 5.17.5.2 Hospitals & clinics

6 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 RECURRING PURCHASE FOR HIGH VOLUME OF DIAGNOSTIC TESTING TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 GROWING NEED FOR AUTOMATION AND HIGH-THROUGHPUT TESTING TO DRIVE MARKET

7 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
• 7.2 AUTOANTIBODIES AND IMMUNOLOGIC TESTS
  • 7.2.1 ACCURATE DETECTION & MONITORING ABILITIES FOR BROAD APPLICATIONS TO PROPEL MARKET
• 7.3 ROUTINE LABORATORY TESTS
  • 7.3.1 RECURRENT TESTING DUE TO COST EFFICIENCY TO BOOST DEMAND
• 7.4 INFLAMMATORY TESTS
  • 7.4.1 ABILITY OF INFLAMMATORY MARKERS TO DETECT ABNORMALITIES TO DRIVE MARKET
• 7.5 URINALYSIS TESTS
  • 7.5.1 TECHNOLOGICAL ADVANCEMENTS IN URINE ANALYZERS TO FUEL UPTAKE
• 7.6 OTHER TESTS

8 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE

• 8.1 INTRODUCTION
• 8.2 SYSTEMIC AUTOIMMUNE DISEASES
  • 8.2.1 RHEUMATOID ARTHRITIS
    • 8.2.1.1 Uptake of rheumatoid factor immunological test to boost demand
  • 8.2.2 SYSTEMIC LUPUS ERYTHEMATOSUS
    • 8.2.2.1 Utilization of autoimmune testing kits for constant monitoring to propel market
  • 8.2.3 PSORIASIS
    • 8.2.3.1 Frequent association with systemic inflammation and comorbidities to boost demand
  • 8.2.4 MULTIPLE SCLEROSIS
    • 8.2.4.1 Public-private investments for MS awareness to fuel market
  • 8.2.5 OTHER SYSTEMIC AUTOIMMUNE DISEASES
• 8.3 ORGAN-SPECIFIC AUTOIMMUNE DISEASES
  • 8.3.1 TYPE-1 DIABETES
    • 8.3.1.1 Rising global incidence among children & adults to fuel market
  • 8.3.2 CELIAC DISEASE
    • 8.3.2.1 Growing awareness regarding gluten sensitivity and improved testing availability to drive market
  • 8.3.3 INFLAMMATORY BOWEL DISEASE
    • 8.3.3.1 Growing awareness of chronic gastrointestinal autoimmune disorders to fuel market
  • 8.3.4 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASES

9 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 CLINICAL LABORATORIES
  • 9.2.1 ABILITY TO CONDUCT HIGH VOLUME OF SPECIALIZED TESTS TO PROPEL MARKET
• 9.3 HOSPITALS & CLINICS
  • 9.3.1 GROWING AWARENESS OF EARLY DISEASE DIAGNOSIS TO FUEL UPTAKE
• 9.4 OTHER END USERS

10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 High healthcare expenditure and expansive research initiatives for product commercialization to boost demand
  • 10.2.3 CANADA
    • 10.2.3.1 Rising prevalence of chronic autoimmune conditions to drive market
• 10.3 EUROPE
  • 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 10.3.2 UK
    • 10.3.2.1 Growing R&D efforts for early disease diagnosis to fuel uptake
  • 10.3.3 GERMANY
    • 10.3.3.1 Increasing incidence of multiple sclerosis to drive market
  • 10.3.4 FRANCE
    • 10.3.4.1 Expansion of lab modernization to support market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Growing disease burden and aging demographics to fuel market
  • 10.3.6 SPAIN
    • 10.3.6.1 Prevalence of celiac disease to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 10.4.2 CHINA
    • 10.4.2.1 Government initiatives for early autoimmune disease screening to fuel market
  • 10.4.3 JAPAN
    • 10.4.3.1 Rapidly aging population and advanced healthcare infrastructure to boost demand
  • 10.4.4 INDIA
    • 10.4.4.1 Government-led healthcare initiatives and rapid expansion of diagnostic infrastructure to propel market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Increasing incidences of autoimmune diseases to support market growth
  • 10.4.6 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 INCREASING INCIDENCE OF TYPE-1 DIABETES TO FUEL MARKET
  • 10.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 FAVORABLE GOVERNMENT INITIATIVES FOR EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH
  • 10.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET
• 11.3 REVENUE ANALYSIS, 2022-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Test type footprint
    • 11.5.5.5 Disease type footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of startups/SMEs
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Key strengths
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses & competitive threats
  • 12.1.2 ABBOTT LABORATORIES
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Key strengths
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses & competitive threats
  • 12.1.3 REVVITY, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 THERMO FISHER SCIENTIFIC INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
      • 12.1.4.3.2 Deals
      • 12.1.4.3.3 Other developments
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 SIEMENS HEALTHINEERS AG
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product approvals
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 BIO-RAD LABORATORIES, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 GRIFOLS S.A.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 WERFEN S.A.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product approvals
  • 12.1.9 EXAGEN INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
  • 12.1.10 TRINITY BIOTECH PLC
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 TECAN GROUP LTD.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 DANAHER CORPORATION
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Deals
  • 12.1.13 BIOSYNEX SA
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Deals
  • 12.1.14 QUIDELORTHO CORPORATION
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Expansions
  • 12.1.15 BIOMERIEUX SA
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
  • 12.1.16 DIASORIN S.P.A.
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 BECTON, DICKINSON AND COMPANY
  • 12.2.2 SD BIOSENSOR, INC.
  • 12.2.3 CAMBRIDGE LIFE SCIENCES LTD
  • 12.2.4 A. MENARINI DIAGNOSTICS S.R.L
  • 12.2.5 SEBIA
  • 12.2.6 KRONUS
  • 12.2.7 ERBA GROUP
  • 12.2.8 AESKU.GROUP GMBH
  • 12.2.9 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
  • 12.2.10 EPITOPE DIAGNOSTICS INC.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS